BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Giacobbe DR, Bassetti M, De Rosa FG, Del Bono V, Grossi PA, Menichetti F, Pea F, Rossolini GM, Tumbarello M, Viale P, Viscoli C; on behalf of ISGRI-SITA (Italian Study Group on Resistant Infections of the Società Italiana Terapia Antinfettiva). Ceftolozane/tazobactam: place in therapy. Expert Review of Anti-infective Therapy 2018;16:307-20. [DOI: 10.1080/14787210.2018.1447381] [Cited by in Crossref: 48] [Cited by in F6Publishing: 52] [Article Influence: 12.0] [Reference Citation Analysis]
Number Citing Articles
1 Karaiskos I, Lagou S, Pontikis K, Rapti V, Poulakou G. The "Old" and the "New" Antibiotics for MDR Gram-Negative Pathogens: For Whom, When, and How. Front Public Health 2019;7:151. [PMID: 31245348 DOI: 10.3389/fpubh.2019.00151] [Cited by in Crossref: 73] [Cited by in F6Publishing: 72] [Article Influence: 24.3] [Reference Citation Analysis]
2 Sader HS, Carvalhaes CG, Duncan LR, Shortridge D. Antimicrobial Activity of Ceftolozane-Tazobactam and Comparators against Clinical Isolates of Haemophilus influenzae from the United States and Europe. Antimicrob Agents Chemother 2020;64:e00211-20. [PMID: 32094135 DOI: 10.1128/AAC.00211-20] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
3 Ortiz de la Rosa JM, Nordmann P, Poirel L. ESBLs and resistance to ceftazidime/avibactam and ceftolozane/tazobactam combinations in Escherichia coli and Pseudomonas aeruginosa. J Antimicrob Chemother 2019;74:1934-9. [PMID: 31225611 DOI: 10.1093/jac/dkz149] [Cited by in Crossref: 32] [Cited by in F6Publishing: 28] [Article Influence: 16.0] [Reference Citation Analysis]
4 Paprocka P, Durnaś B, Mańkowska A, Skłodowski K, Król G, Zakrzewska M, Czarnowski M, Kot P, Fortunka K, Góźdź S, Savage PB, Bucki R. New β-Lactam Antibiotics and Ceragenins - A Study to Assess Their Potential in Treatment of Infections Caused by Multidrug-Resistant Strains of Pseudomonas aeruginosa. Infect Drug Resist 2021;14:5681-98. [PMID: 34992394 DOI: 10.2147/IDR.S338827] [Reference Citation Analysis]
5 Giacobbe DR, Corcione S, Salsano A, Del Puente F, Mornese Pinna S, De Rosa FG, Mikulska M, Santini F, Viscoli C. Current and emerging pharmacotherapy for the treatment of infections following open-heart surgery. Expert Opin Pharmacother 2019;20:751-72. [PMID: 30785333 DOI: 10.1080/14656566.2019.1574753] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
6 Fodor A, Abate BA, Deák P, Fodor L, Gyenge E, Klein MG, Koncz Z, Muvevi J, Ötvös L, Székely G, Vozik D, Makrai L. Multidrug Resistance (MDR) and Collateral Sensitivity in Bacteria, with Special Attention to Genetic and Evolutionary Aspects and to the Perspectives of Antimicrobial Peptides-A Review. Pathogens 2020;9:E522. [PMID: 32610480 DOI: 10.3390/pathogens9070522] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
7 Pezzi M, Scozzafava AM, Giglio AM, Vozzo R, Casella PD, Tiburzi SP, Cosco L, Verre M. Use of Ceftolozane/Tazobactam in a Case of Septic Shock by Puerperal Sepsis. Case Rep Obstet Gynecol 2019;2019:8463693. [PMID: 31275681 DOI: 10.1155/2019/8463693] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
8 Los-Arcos I, Burgos J, Falcó V, Almirante B. An overview of ceftolozane sulfate + tazobactam for treating hospital acquired pneumonia. Expert Opin Pharmacother 2020;21:1005-13. [PMID: 32212866 DOI: 10.1080/14656566.2020.1739269] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
9 Hayes JF. Fighting Back against Antimicrobial Resistance with Comprehensive Policy and Education: A Narrative Review. Antibiotics 2022;11:644. [DOI: 10.3390/antibiotics11050644] [Reference Citation Analysis]
10 Bassetti M, Eckmann C, Giacobbe DR, Sartelli M, Montravers P. Post-operative abdominal infections: epidemiology, operational definitions, and outcomes. Intensive Care Med 2020;46:163-72. [PMID: 31701205 DOI: 10.1007/s00134-019-05841-5] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
11 Ronda M, Pérez-Recio S, González Laguna M, Tubau Quintano MF, Llop Talaveron J, Soldevila-Boixader L, Carratalà J, Cuervo G, Padullés A. Ceftolozane/tazobactam for difficult-to-treat Gram-negative infections: A real-world tertiary hospital experience. J Clin Pharm Ther 2022. [PMID: 35255527 DOI: 10.1111/jcpt.13623] [Reference Citation Analysis]
12 Saran O, Sulik-Tyszka B, Basak GW, Wróblewska MM. Activity of Ceftolozane/Tazobactam Against Gram-Negative Rods of the Family Enterobacteriaceae and Pseudomonas Spp. Isolated from Onco-Hematological Patients Hospitalized in a Clinical Hospital in Poland. Med Sci Monit 2019;25:305-11. [PMID: 30628586 DOI: 10.12659/MSM.913352] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
13 Cantón R, Loza E, Arcay RM, Cercenado E, Castillo FJ, Cisterna R, Gálvez-Benítez L, González Romo F, Hernández-Cabezas A, Rodríguez-Lozano J, Suárez-Barrenechea AI, Tubau F, Díaz-Regañón J, López-Mendoza D; SMART-Spain Working Group. Antimicrobial activity of ceftolozane-tazobactam against Enterobacterales and Pseudomonas aeruginosa recovered during the Study for Monitoring Antimicrobial Resistance Trends (SMART) program in Spain (2016-2018). Rev Esp Quimioter 2021;34:228-37. [PMID: 33645948 DOI: 10.37201/req/019.2021] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
14 Del Giacomo P, Losito AR, Tumbarello M. The role of carbapenem-resistant pathogens in cSSTI and how to manage them: . Current Opinion in Infectious Diseases 2019;32:113-22. [DOI: 10.1097/qco.0000000000000528] [Cited by in Crossref: 4] [Article Influence: 1.3] [Reference Citation Analysis]
15 Bassetti M, Castaldo N, Cattelan A, Mussini C, Righi E, Tascini C, Menichetti F, Mastroianni CM, Tumbarello M, Grossi P, Artioli S, Carannante N, Cipriani L, Coletto D, Russo A, Digaetano M, Losito AR, Peghin M, Capone A, Nicolè S, Vena A; CEFTABUSE Study Group. Ceftolozane/tazobactam for the treatment of serious Pseudomonas aeruginosa infections: a multicentre nationwide clinical experience. Int J Antimicrob Agents 2019;53:408-15. [PMID: 30415002 DOI: 10.1016/j.ijantimicag.2018.11.001] [Cited by in Crossref: 62] [Cited by in F6Publishing: 62] [Article Influence: 15.5] [Reference Citation Analysis]
16 Losito AR, Raffaelli F, Del Giacomo P, Tumbarello M. New Drugs for the Treatment of Pseudomonas aeruginosa Infections with Limited Treatment Options: A Narrative Review. Antibiotics 2022;11:579. [DOI: 10.3390/antibiotics11050579] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
17 Criscuolo M, Trecarichi EM. Ceftazidime/Avibactam and Ceftolozane/Tazobactam for Multidrug-Resistant Gram Negatives in Patients with Hematological Malignancies: Current Experiences. Antibiotics (Basel) 2020;9:E58. [PMID: 32028615 DOI: 10.3390/antibiotics9020058] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
18 Kanwar N, Banerjee D, Harrison CJ, Newland JG, Qin X, Zerr DM, Zaoutis T, Selvarangan R. Comparative in vitro effectiveness of ceftolozane/tazobactam against pediatric gram-negative drug-resistant isolates. J Chemother 2021;33:288-93. [PMID: 33645447 DOI: 10.1080/1120009X.2021.1888030] [Reference Citation Analysis]
19 Bitar I, Salloum T, Merhi G, Hrabak J, Araj GF, Tokajian S. Genomic Characterization of Mutli-Drug Resistant Pseudomonas aeruginosa Clinical Isolates: Evaluation and Determination of Ceftolozane/Tazobactam Activity and Resistance Mechanisms. Front Cell Infect Microbiol 2022;12:922976. [DOI: 10.3389/fcimb.2022.922976] [Reference Citation Analysis]
20 Bassetti M, Giacobbe DR, Robba C, Pelosi P, Vena A. Treatment of extended-spectrum β-lactamases infections: what is the current role of new β-lactams/β-lactamase inhibitors? Curr Opin Infect Dis 2020;33:474-81. [PMID: 33060469 DOI: 10.1097/QCO.0000000000000685] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
21 Lizza BD, Betthauser KD, Ritchie DJ, Micek ST, Kollef MH. New Perspectives on Antimicrobial Agents: Ceftolozane-Tazobactam. Antimicrob Agents Chemother 2021;65:e0231820. [PMID: 33875428 DOI: 10.1128/AAC.02318-20] [Reference Citation Analysis]
22 Giacobbe DR, Ciacco E, Girmenia C, Pea F, Rossolini GM, Sotgiu G, Tascini C, Tumbarello M, Viale P, Bassetti M; ISGRI-SITA (Italian Study Group on Resistant Infections of the Italian Society of Anti-infective Therapy). Evaluating Cefiderocol in the Treatment of Multidrug-Resistant Gram-Negative Bacilli: A Review of the Emerging Data. Infect Drug Resist 2020;13:4697-711. [PMID: 33402840 DOI: 10.2147/IDR.S205309] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
23 Tehrani KHME, Martin NI. β-lactam/β-lactamase inhibitor combinations: an update. Medchemcomm 2018;9:1439-56. [PMID: 30288219 DOI: 10.1039/c8md00342d] [Cited by in Crossref: 58] [Cited by in F6Publishing: 27] [Article Influence: 14.5] [Reference Citation Analysis]
24 Corcione S, Lupia T, De Rosa FG. Novel Cephalosporins in Septic Subjects and Severe Infections: Present Findings and Future Perspective. Front Med (Lausanne) 2021;8:617378. [PMID: 34026774 DOI: 10.3389/fmed.2021.617378] [Reference Citation Analysis]
25 Lupia T, Corcione S, Mornese Pinna S, De Rosa FG. New cephalosporins for the treatment of pneumonia in internal medicine wards. J Thorac Dis 2020;12:3747-63. [PMID: 32802454 DOI: 10.21037/jtd-20-417] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
26 Papp-Wallace KM. The latest advances in β-lactam/β-lactamase inhibitor combinations for the treatment of Gram-negative bacterial infections. Expert Opin Pharmacother 2019;20:2169-84. [PMID: 31500471 DOI: 10.1080/14656566.2019.1660772] [Cited by in Crossref: 42] [Cited by in F6Publishing: 37] [Article Influence: 14.0] [Reference Citation Analysis]
27 Giacobbe DR, Mora S, Giacomini M, Bassetti M. Machine Learning and Multidrug-Resistant Gram-Negative Bacteria: An Interesting Combination for Current and Future Research. Antibiotics (Basel) 2020;9:E54. [PMID: 32023986 DOI: 10.3390/antibiotics9020054] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
28 Karaiskos I, Giamarellou H. Carbapenem-Sparing Strategies for ESBL Producers: When and How. Antibiotics (Basel) 2020;9:E61. [PMID: 32033322 DOI: 10.3390/antibiotics9020061] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 11.5] [Reference Citation Analysis]
29 Bassetti M, Righi E, Vena A, Graziano E, Russo A, Peghin M. Risk stratification and treatment of ICU-acquired pneumonia caused by multidrug- resistant/extensively drug-resistant/pandrug-resistant bacteria. Curr Opin Crit Care 2018;24:385-93. [PMID: 30156569 DOI: 10.1097/MCC.0000000000000534] [Cited by in Crossref: 36] [Cited by in F6Publishing: 11] [Article Influence: 12.0] [Reference Citation Analysis]
30 Ottino L, Bartalesi F, Borchi B, Bresci S, Cavallo A, Baccani I, Rossolini GM, Bartoloni A. Ceftolozane/tazobactam for Pseudomonas aeruginosa pulmonary exacerbations in cystic fibrosis adult patients: a case series. Eur J Clin Microbiol Infect Dis 2021. [PMID: 33709301 DOI: 10.1007/s10096-021-04218-1] [Reference Citation Analysis]
31 Carcione D, Siracusa C, Sulejmani A, Leoni V, Intra J. Old and New Beta-Lactamase Inhibitors: Molecular Structure, Mechanism of Action, and Clinical Use. Antibiotics (Basel) 2021;10:995. [PMID: 34439045 DOI: 10.3390/antibiotics10080995] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
32 Murri R, Sacco E. What place does ceftolozane/tazobactam have in the treatment of complicated urinary-tract infections? Expert Opin Pharmacother 2021;22:1377-9. [PMID: 33849371 DOI: 10.1080/14656566.2021.1915286] [Reference Citation Analysis]
33 Poulakou G, Lagou S, Karageorgopoulos DE, Dimopoulos G. New treatments of multidrug-resistant Gram-negative ventilator-associated pneumonia. Ann Transl Med 2018;6:423. [PMID: 30581831 DOI: 10.21037/atm.2018.10.29] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 3.3] [Reference Citation Analysis]
34 Bassetti M, Giacobbe DR, Vena A, Brink A. Challenges and research priorities to progress the impact of antimicrobial stewardship. Drugs Context 2019;8:212600. [PMID: 31516534 DOI: 10.7573/dic.212600] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
35 Alvarez-Buylla A, Allen M, Betts D, Bennett S, Monahan I, Planche T; INVICTUS study group . Multicentre study of the in vitro activity of ceftolozane/tazobactam and other commonly used antibiotics against Pseudomonas aeruginosa isolates from patients in the UK. JAC Antimicrob Resist 2020;2:dlaa024. [PMID: 34222988 DOI: 10.1093/jacamr/dlaa024] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
36 Bassetti M, Graziano E, Berruti M, Giacobbe DR. The role of fosfomycin for multidrug-resistant gram-negative infections. Curr Opin Infect Dis 2019;32:617-25. [PMID: 31567411 DOI: 10.1097/QCO.0000000000000597] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 3.5] [Reference Citation Analysis]
37 Saroha B, Kumar G, Kumar R, Kumari M, Kumar S. A minireview of 1,2,3-triazole hybrids with O-heterocycles as leads in medicinal chemistry. Chem Biol Drug Des 2021. [PMID: 34592059 DOI: 10.1111/cbdd.13966] [Reference Citation Analysis]
38 Bassetti M, Vena A, Battaglini D, Pelosi P, Giacobbe DR. The role of new antimicrobials for Gram-negative infections in daily clinical practice. Curr Opin Infect Dis 2020;33:495-500. [PMID: 33009142 DOI: 10.1097/QCO.0000000000000686] [Reference Citation Analysis]
39 Giacobbe DR, Saffioti C, Losito AR, Rinaldi M, Aurilio C, Bolla C, Boni S, Borgia G, Carannante N, Cassola G, Ceccarelli G, Corcione S, Dalla Gasperina D, De Rosa FG, Dentone C, Di Bella S, Di Lauria N, Feasi M, Fiore M, Fossati S, Franceschini E, Gori A, Granata G, Grignolo S, Grossi PA, Guadagnino G, Lagi F, Maraolo AE, Marinò V, Mazzitelli M, Mularoni A, Oliva A, Pace MC, Parisini A, Patti F, Petrosillo N, Pota V, Raffaelli F, Rossi M, Santoro A, Tascini C, Torti C, Trecarichi EM, Venditti M, Viale P, Signori A, Bassetti M, Del Bono V, Giannella M, Mikulska M, Tumbarello M, Viscoli C; SITA GIOVANI (Young Investigators Group of the Società Italiana Terapia Antinfettiva) and the COLI-CROSS Study Group. Use of colistin in adult patients: A cross-sectional study. J Glob Antimicrob Resist 2020;20:43-9. [PMID: 31207379 DOI: 10.1016/j.jgar.2019.06.009] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
40 Bassetti M, Vena A, Russo A, Croxatto A, Calandra T, Guery B. Rational approach in the management of Pseudomonas aeruginosa infections. Curr Opin Infect Dis 2018;31:578-86. [PMID: 30299364 DOI: 10.1097/QCO.0000000000000505] [Cited by in Crossref: 18] [Cited by in F6Publishing: 8] [Article Influence: 6.0] [Reference Citation Analysis]
41 Grossi PA. Donor-derived infections, lessons learnt from the past, and what is the future going to bring us. Curr Opin Organ Transplant 2018;23:417-22. [PMID: 29916849 DOI: 10.1097/MOT.0000000000000551] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
42 Jaiswal SR, Gupta S, Kumar RS, Sherawat A, Rajoreya A, Dash SK, Bhagwati G, Chakrabarti S. Gut Colonization with Carbapenem-resistant Enterobacteriaceae Adversely Impacts the Outcome in Patients with Hematological Malignancies: Results of A Prospective Surveillance Study. Mediterr J Hematol Infect Dis 2018;10:e2018025. [PMID: 29755703 DOI: 10.4084/MJHID.2018.025] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
43 Lence E, González‐bello C. Bicyclic Boronate β‐Lactamase Inhibitors: The Present Hope against Deadly Bacterial Pathogens. Adv Therap 2021;4:2000246. [DOI: 10.1002/adtp.202000246] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
44 Poirel L, Ortiz De La Rosa JM, Kieffer N, Dubois V, Jayol A, Nordmann P. Acquisition of Extended-Spectrum β-Lactamase GES-6 Leading to Resistance to Ceftolozane-Tazobactam Combination in Pseudomonas aeruginosa. Antimicrob Agents Chemother 2019;63:e01809-18. [PMID: 30323045 DOI: 10.1128/AAC.01809-18] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 2.8] [Reference Citation Analysis]
45 Bassetti M, Peghin M, Vena A, Giacobbe DR. Treatment of Infections Due to MDR Gram-Negative Bacteria. Front Med (Lausanne) 2019;6:74. [PMID: 31041313 DOI: 10.3389/fmed.2019.00074] [Cited by in Crossref: 81] [Cited by in F6Publishing: 77] [Article Influence: 27.0] [Reference Citation Analysis]
46 Bassetti M, Mularoni A, Giacobbe DR, Castaldo N, Vena A. New Antibiotics for Hospital-Acquired Pneumonia and Ventilator-Associated Pneumonia. Semin Respir Crit Care Med 2022. [PMID: 35088403 DOI: 10.1055/s-0041-1740605] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
47 Carvalhaes CG, Castanheira M, Sader HS, Flamm RK, Shortridge D. Antimicrobial activity of ceftolozane-tazobactam tested against gram-negative contemporary (2015-2017) isolates from hospitalized patients with pneumonia in US medical centers. Diagn Microbiol Infect Dis 2019;94:93-102. [PMID: 30642717 DOI: 10.1016/j.diagmicrobio.2018.11.021] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 5.0] [Reference Citation Analysis]
48 Papp-Wallace KM, Mack AR, Taracila MA, Bonomo RA. Resistance to Novel β-Lactam-β-Lactamase Inhibitor Combinations: The "Price of Progress". Infect Dis Clin North Am 2020;34:773-819. [PMID: 33011051 DOI: 10.1016/j.idc.2020.05.001] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 5.5] [Reference Citation Analysis]
49 Bassetti M, Giacobbe DR, Castaldo N, Russo A, Vena A. Role of new antibiotics in extended-spectrum β-lactamase-, AmpC- infections. Curr Opin Infect Dis 2021;34:748-55. [PMID: 34581282 DOI: 10.1097/QCO.0000000000000789] [Reference Citation Analysis]
50 Bassetti M, Vena A, Sepulcri C, Giacobbe DR, Peghin M. Treatment of Bloodstream Infections Due to Gram-Negative Bacteria with Difficult-to-Treat Resistance. Antibiotics (Basel) 2020;9:E632. [PMID: 32971809 DOI: 10.3390/antibiotics9090632] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
51 Jalde SS, Choi HK. Recent advances in the development of β-lactamase inhibitors. J Microbiol 2020;58:633-47. [PMID: 32720096 DOI: 10.1007/s12275-020-0285-z] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
52 Petrosillo N, Granata G, Boyle B, Doyle MM, Pinchera B, Taglietti F. Preventing sepsis development in complicated urinary tract infections. Expert Rev Anti Infect Ther 2020;18:47-61. [PMID: 31795788 DOI: 10.1080/14787210.2020.1700794] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
53 Sime FB, Lassig-Smith M, Starr T, Stuart J, Pandey S, Parker SL, Wallis SC, Lipman J, Roberts JA. Population Pharmacokinetics of Unbound Ceftolozane and Tazobactam in Critically Ill Patients without Renal Dysfunction. Antimicrob Agents Chemother 2019;63:e01265-19. [PMID: 31358583 DOI: 10.1128/AAC.01265-19] [Cited by in Crossref: 16] [Cited by in F6Publishing: 8] [Article Influence: 5.3] [Reference Citation Analysis]
54 Smibert OC, Paraskeva MA, Westall G, Snell G. An Update in Antimicrobial Therapies and Infection Prevention in Pediatric Lung Transplant Recipients. Paediatr Drugs 2018;20:539-53. [PMID: 30187362 DOI: 10.1007/s40272-018-0313-1] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
55 Bassetti M, Russo C, Vena A, Giacobbe DR. New antibiotics for the treatment of nonfermenting Gram-negative bacteria. Curr Opin Infect Dis 2021;34:701-9. [PMID: 34637210 DOI: 10.1097/QCO.0000000000000757] [Reference Citation Analysis]
56 Xu E, Pérez-Torres D, Fragkou PC, Zahar JR, Koulenti D. Nosocomial Pneumonia in the Era of Multidrug-Resistance: Updates in Diagnosis and Management. Microorganisms 2021;9:534. [PMID: 33807623 DOI: 10.3390/microorganisms9030534] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
57 Aguilera-Alonso D, Escosa-García L, Saavedra-Lozano J, Cercenado E, Baquero-Artigao F. Carbapenem-Resistant Gram-Negative Bacterial Infections in Children. Antimicrob Agents Chemother 2020;64:e02183-19. [PMID: 31844014 DOI: 10.1128/AAC.02183-19] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
58 Shorr AF, Zilberberg MD. Novelty and nuance in the intensive care unit: new options to combat multidrug resistant pneumonia. Curr Opin Infect Dis 2021;34:151-5. [PMID: 33395092 DOI: 10.1097/QCO.0000000000000712] [Reference Citation Analysis]
59 Motos A, Li Bassi G, Pagliara F, Fernandez-Barat L, Yang H, Aguilera Xiol E, Senussi T, Idone FA, Travierso C, Chiurazzi C, Amaro R, Yang M, Bobi J, Rigol M, Nicolau DP, Frigola G, Cabrera R, Ramirez J, Pelosi P, Blasi F, Antonelli M, Artigas A, Vila J, Kollef M, Torres A. Short-Term Effects of Appropriate Empirical Antimicrobial Treatment with Ceftolozane/Tazobactam in a Swine Model of Nosocomial Pneumonia. Antimicrob Agents Chemother 2021;65:e01899-20. [PMID: 33168605 DOI: 10.1128/AAC.01899-20] [Reference Citation Analysis]
60 Bassetti M, Vena A, Giacobbe DR, Falcone M, Tiseo G, Giannella M, Pascale R, Meschiari M, Digaetano M, Oliva A, Rovelli C, Carannante N, Losito AR, Carbonara S, Mariani MF, Mastroianni A, Angarano G, Tumbarello M, Tascini C, Grossi P, Mastroianni CM, Mussini C, Viale P, Menichetti F, Viscoli C, Russo A; CEFTABUSE Study Group . Ceftolozane/Tazobactam for Treatment of Severe ESBL-Producing Enterobacterales Infections: A Multicenter Nationwide Clinical Experience (CEFTABUSE II Study). Open Forum Infect Dis 2020;7:ofaa139. [PMID: 32462046 DOI: 10.1093/ofid/ofaa139] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 8.0] [Reference Citation Analysis]
61 Garazzino S, Altieri E, Silvestro E, Pruccoli G, Scolfaro C, Bignamini E. Ceftolozane/Tazobactam for Treating Children With Exacerbations of Cystic Fibrosis Due to Pseudomonas aeruginosa: A Review of Available Data. Front Pediatr 2020;8:173. [PMID: 32432060 DOI: 10.3389/fped.2020.00173] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
62 Giacobbe DR, Mikulska M, Viscoli C. Recent advances in the pharmacological management of infections due to multidrug-resistant Gram-negative bacteria. Expert Review of Clinical Pharmacology 2018;11:1219-36. [DOI: 10.1080/17512433.2018.1549487] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 7.0] [Reference Citation Analysis]
63 Siddiqui MM, Nagargoje AA, Akolkar SV, Sangshetti JN, Khedkar VM, Pisal PM, Shingate BB. [HDBU][HSO4]-catalyzed facile synthesis of new 1,2,3-triazole-tethered 2,3-dihydroquinazolin-4[1H]-one derivatives and their DPPH radical scavenging activity. Res Chem Intermed. [DOI: 10.1007/s11164-021-04639-9] [Reference Citation Analysis]